Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies

  • O. Abdel-Rahman
Brief Research Article



The current analysis aims to evaluate the impact of statin co-treatment on the survival of patients with metastatic pancreatic cancer.


This is a pooled analysis of de-identified patient data from two clinical trials (NCT01124786; NCT00844649). Overall and progression-free survival according to patient subsets (patients who received or who did not receive statins) were assessed through Kaplan–Meier analysis and log-rank test. Univariate and multivariate Cox regression analysis was performed to evaluate different factors potentially affecting overall and progression-free survival. Propensity score matching was performed to address heterogeneity in baseline characteristics of different subgroups of patients.


A total of 797 patients were assessed in the current study; of which 156 patients received statins and 641 did not receive statins. Using Kaplan–Meier survival estimates, patients who received statins seem to have better overall and progression-free survival compared to patients who did not (P = 0.008; P < 0.001, respectively). In multivariate analysis for factors affecting overall survival, the following factors were associated with worse overall survival: worse performance status (P < 0.001), no statin use (P = 0.044) and multiple sites of metastatic disease (P = 0.023); likewise in multivariate analysis for factors affecting progression-free survival, the following factors were associated with worse progression-free survival: worse performance status (P < 0.001), gemcitabine elaidate chemotherapy (P = 0.015) and no statin use (P = 0.048). Following propensity score matching and using Kaplan–Meier estimates, statin use was also associated with better overall and progression-free survival (P = 0.005; P = 0.040, respectively).


Statin use seems to be associated with better overall survival among patients with metastatic pancreatic cancer treated with first-line chemotherapy. Prospective studies designed specifically to assess this potential effect of statins are needed.


Metastatic pancreatic cancer Chemotherapy Statins Outcomes 



There is no funding for this study.

Compliance with ethical standards

Conflict of interest

There is no conflicts of interest.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in the two studies.


  1. 1.
    Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–705.CrossRefGoogle Scholar
  2. 2.
    Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018;18(1):688.CrossRefGoogle Scholar
  3. 3.
    Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083–93.CrossRefGoogle Scholar
  4. 4.
    Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, et al. Comorbidity,age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA. 3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012;48(10):1434–42.CrossRefGoogle Scholar
  5. 5.
    Wang F, Herrington M, Larsson J. Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003;2:4-.CrossRefGoogle Scholar
  6. 6.
    Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11(3):306–15.CrossRefGoogle Scholar
  7. 7.
    Chae YK, Yousaf M, Malecek MK, Carneiro B, Chandra S, Kaplan J, et al. Statins as anti-cancer therapy; can we translate preclinical and epidemiologic data into clinical benefit? Discov Med. 2015;20(112):413–27.PubMedGoogle Scholar
  8. 8.
    Lee HS, Lee SH, Lee HJ, Chung MJ, Park JY, Park SW, et al. Statin use and its impact on survival in pancreatic cancer patients. Medicine. 2016;95(19):e3607.CrossRefGoogle Scholar
  9. 9.
    Jeon CY, Pandol SJ, Wu B, Cook-Wiens G, Gottlieb RA, Merz CN, et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One. 2015;10(4):e0121783.CrossRefGoogle Scholar
  10. 10.
    Project data sphere. Accessed 1 Nov 2018.
  11. 11.
    Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hent1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013;31(35):4453–61.CrossRefGoogle Scholar
  12. 12.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefGoogle Scholar
  13. 13.
    Ciofu C. The statins as anticancer agents. Maedica. 2012;7(4):377.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Wu BU, Chang J, Jeon CY, Pandol SJ, Huang B, Ngor EW, et al. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol. 2015;110(8):1233–9.CrossRefGoogle Scholar
  15. 15.
    Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, et al. Prediagnosis use of statins associates with increased survival times of patients with pancreatic cancer. Clin Gastroenterol Hepatol. 2018;16(8):1300.e3–1306.e3.CrossRefGoogle Scholar
  16. 16.
    Huang BZ, Chang JI, Li E, Xiang AH, Wu BU. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J Natl Cancer Inst. 2016;109(5).CrossRefGoogle Scholar
  17. 17.
    Li X, Li T, Liu Z, Gou S, Wang C. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep. 2017;7(1):5825.CrossRefGoogle Scholar
  18. 18.
    Dong Y-W, Shi Y-Q, He L-W, Cui X-Y, Su P-Z. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget. 2017;8(33):55478–88.PubMedPubMedCentralGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Clinical Oncology Department, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Department of OncologyUniversity of Calgary and Tom Baker Cancer CenterCalgaryCanada

Personalised recommendations